In 2019, SARS-CoV-2 emerged as a novel pathogen causing coronavirus disease 2019 (COVID-19). Categorised as a pandemic by the World Health Organisation (WHO) in March 2020, COVID-19 has affected multiple countries across all populated continents. Rapid testing plays an important role as societies seek to contain, delay and mitigate the effects of the outbreak.
Many labs are in need of a rapid and specific detection method to assist with outbreak management.
The WHO recommends that suspected cases are screened by nucleic acid amplification tests.
The FluoroType® SARS-CoV-2 plus is a CE-IVD kit, which provides for the detection of two independent SARS-CoV-2 genes while simultaneously differentiating endemic human coronaviruses. The multiplex real-time PCR kit is compatible with a range of common thermocyclers.
For maximum efficiency, ‘results at a glance’ are available when using the kit with the FluoroCycler® XT and integrated software tool. This high performance PCR system analyses all run components and provides an unambiguous report in less than two hours.
Hain Lifescience GmbH - a Bruker company
Hain Lifescience Spain SL - a Bruker Company
Biocentric - a Bruker Company
Bruker UK Ltd.